Advanced Search

Technical Analysis for KYMR - Kymera Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 31.62 2.70% 0.83
KYMR closed down 0.16 percent on Monday, September 28, 2020, on 70 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical KYMR trend table...
Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 2.70%
Inside Day Range Contraction 2.70%
Crossed Above 20 DMA Bullish 2.53%
Multiple of Ten Bullish Other 2.53%
Outside Day Range Expansion 2.53%
20 DMA Resistance Bearish 5.72%
Narrow Range Bar Range Contraction 5.72%
Multiple of Ten Bearish Other 5.72%
20 DMA Resistance Bearish 5.47%
Hot IPO Pullback Bullish Swing Setup 5.47%
Older End-of-Day Gignals for KYMR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 3 hours ago
60 Minute Opening Range Breakout about 4 hours ago
Hot IPO Pullback Entry about 4 hours ago
Rose Above Previous Day's High about 4 hours ago
Up 3% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

Kymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation by accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins to address previously intractable disease targets
Biopharmaceutical Machinery

Is KYMR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Sep 18 Kymera Therapeutics (KYMR) Presents At Morgan Stanley 18th Annual Global Healthcare Conference - Slideshow
Sep 14 Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
Sep 13 The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Sep 10 The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Sep 9 The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment
Sep 9 Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors
Aug 27 Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
Aug 25 Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Aug 25 The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout
Aug 21 Kymera Therapeutics prices upsized IPO beyond range at $20
See more KYMR news...

Indicators

Indicator Value
52 Week High 37.75
52 Week Low 25.43
Average Volume 228,903
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 30.08
10-Day Moving Average 30.05
Average True Range 2.75
ADX 8.08
+DI 16.34
-DI 12.76
Chandelier Exit (Long, 3 ATRs ) 26.55
Chandelier Exit (Short, 3 ATRs ) 33.68
Upper Bollinger Band 33.03
Lower Bollinger Band 27.14
Percent B (%b) 0.62
BandWidth 19.58
MACD Line -0.21
MACD Signal Line -0.31
MACD Histogram 0.0938
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.86
Resistance 3 (R3) 33.00 32.44 32.52
Resistance 2 (R2) 32.44 31.92 32.38 32.40
Resistance 1 (R1) 31.62 31.59 31.34 31.48 32.28
Pivot Point 31.06 31.06 30.93 31.00 31.06
Support 1 (S1) 30.24 30.54 29.96 30.10 29.30
Support 2 (S2) 29.68 30.21 29.62 29.18
Support 3 (S3) 28.86 29.68 29.07
Support 4 (S4) 28.72